This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (54)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatology, Other  • Alert me on articles by topic

Developments in Biological Skin Substitutes

Arch Dermatol. 1998;134:344-349.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

SINCE 1988, when the status of cultured skin grafts was reviewed in the ARCHIVES,¹ there have been exciting developments in the search for a biological product that can mimic the structure and function of skin. Many skin substitutes have undergone extensive clinical trials; some have been approved by the Food and Drug Administration (FDA) and many are currently undergoing FDA review. In this issue of the ARCHIVES, Falanga et al² report on the results of a pivotal clinical trial using human skin equivalent (HSE) (Apligraf, Organogenesis Inc, Canton, Mass) in the treatment of chronic venous ulcers. This article reviews the following areas: (1) What skin substitutes are available and how does HSE compare with them? (2) How do the results of this study compare with the standard of care for venous ulcers? (3) What are the risks and benefits of treatment with biological skin substitutes? (4) What are the possible . . . [Full Text of this Article]

WHAT SKIN SUBSTITUTES ARE AVAILABLE?

Epidermal Grafts

Dermal Replacements

COMPOSITE GRAFTS

HOW DOES HSE COMPARE WITH OTHER SKIN SUBSTITUTES?

WHAT IS THE STANDARD OF CARE FOR VENOUS ULCERS AND WHAT IS THE EXPECTED HEALING RATE?

WHAT ARE THE RISKS AND BENEFITS OF BIOLOGICAL SKIN SUBSTITUTES?

MECHANISM OF ACTION

HOW WILL THESE PRODUCTS FIT INTO CURRENT CLINICAL PRACTICE?

RELATED ARTICLE

Rapid Healing of Venous Ulcers and Lack of Clinical Rejection With an Allogeneic Cultured Human Skin Equivalent
Vincent Falanga, David Margolis, Oscar Alvarez, Michael Auletta, Frank Maggiacomo, Morton Altman, Jeff Jensen, Michael Sabolinski, Jan Hardin-Young, and and the Human Skin Equivalent Investigators Group
Arch Dermatol. 1998;134(3):293-300.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Longevity of a Bilayered Skin Substitute After Application to Venous Ulcers
Phillips et al.
Arch Dermatol 2002;138:1079-1081.
ABSTRACT | FULL TEXT  

Recent Advances in Wound Healing
Bello and Phillips
JAMA 2000;283:716-718.
FULL TEXT  

Nonoperative Management of Venous Ulcers and the Emerging Role of Bioengineered Skin Substitutes
Lam and Moneta
PERSPECT VASC SURG ENDOVASC THER 2000;13:69-81.
ABSTRACT  

Tissue-Engineered Skin: An Alternative to Split-Thickness Skin Grafts?
Phillips
Arch Dermatol 1999;135:977-978.
FULL TEXT  

Nonoperative Management of Venous Leg Ulcers: Evolving Role of Skin Substitutes
Skin Substitute Consensus Development Panel
VASC ENDOVASCULAR SURG 1999;33:197-210.
ABSTRACT  

Safety Evaluation of Human Living Skin Equivalents
Nemecek and Dayan
Toxicol Pathol 1999;27:101-103.
ABSTRACT  

Human Keratinocytes Express Cellular Prion-Related Protein in Vitro and during Inflammatory Skin Diseases
Pammer et al.
Am. J. Pathol. 1998;153:1353-1358.
ABSTRACT | FULL TEXT  

Questions About Study of Cultured Skin Equivalent for Venous Ulcers
Epstein and Falanga
Arch Dermatol 1998;134:1483-1484.
FULL TEXT  

Human Skin Equivalent for Venous Ulcers
JWatch General 1998;1998:4-4.
FULL TEXT  

In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse
Schechner et al.
Proc. Natl. Acad. Sci. USA 2000;97:9191-9196.
ABSTRACT | FULL TEXT